Hepatitis B is a problem for a growing number of patients on immunosuppressive medications

American Gastroenterological Association recommends antiviral drugs for patients at risk of hepatitis B reactivation.

2025-01-23

(Press-News.org) Bethesda, MD (Jan. 22, 2025) — The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs. The use of immunosuppressive drugs has increased significantly since 2013, according to data gathered via the National Health Interview Survey.

New tailored risk assessments can help health care providers and patients navigate challenges posed by the newer immunosuppressive therapies used for oncology, rheumatology, and gastrointestinal diseases. As the number of immunosuppressive drugs has grown, so has the number of patients referred to gastroenterologists with hepatitis B reactivation, which can lead to acute liver failure.

For patients at high risk of hepatitis B reactivation, AGA recommends preventive antiviral medication. Reactivated HBV can lead to liver damage, hospitalization, and even death. These risks are higher than any potential side effects of antiviral medicines. For at-risk patients who do not initiate prophylactic antiviral medication, a commitment to close monitoring by both patients and providers is essential to prevent missed reactivation. Antiviral treatments are readily available in the U.S.

Both current HBV-positive patients and those with previous HBV exposure, including those with immunity to HBV, are at risk of virus reactivation while on immunosuppressive drugs.

Screening for hepatitis B virus is the first crucial step for patients starting immunosuppressive medications, noted guideline authors. In March 2023, the U.S. Center for Disease Control and Prevention recommended universal HBV screening and testing for all adults in the United States at least once in their lifetime. It should include a “triple” panel of HBsAg, antibodies to HBV surface Ag (anti-HBs), and HBV total core Ag (anti-HBc). Those with positive anti-HBc are at risk for HBVr.

AGA’s guidance is based on a patient’s HBV infection status. Patients are further grouped into low, medium, and high reactivation risk based on which immunosuppressive medication they take.

Risk Categories for HBV-Positive Patients (chronic hepatitis B: positive HBsAg)

High Risk:

Patients on anthracycline derivatives, anti-tumor necrosis factor (TNF) agents, or anti-interleukin-6 (IL-6) therapies. Patients receiving B cell-depleting agents (E.g., rituximab), chimeric antigen receptor (CAR)-T cell therapies, or cytokine/integrin inhibitors. Patients receiving tyrosine kinase inhibitor (TKI) therapies or Janus kinase (JAK) inhibitors. Patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE) HCV co-infected patients undergoing direct-acting antiviral (DAA) therapy. Patients on high doses of corticosteroids for one month or more. Moderate Risk:

Patients treated with anti-T cell therapies. Patients on low-dose corticosteroids for four or more weeks. Low Risk:

Patients on low, moderate, or high doses of corticosteroids for one week or less. Patients receiving intra-articular corticosteroid therapies. Risk Categories for Patients Without Chronic Hepatitis B but Previously Exposed to HBV (negative HBsAg, positive anti-HBc [total or IgG]; anti-HBs can be negative or positive)

High Risk:

Patients receiving rituximab. Moderate Risk:

Patients on anthracycline derivatives, anti-IL-6 therapies, anti-T cell therapies, or CAR-T cell therapies. Patients treated with cytokine/integrin inhibitors, TKI therapies, or JAK inhibitors Patients undergoing TACE. Patients on moderate to high doses of corticosteroids for one month or more. Low Risk:

Patients on immune checkpoint inhibitors or anti-TNF therapies. Patients with HCV co-infection undergoing DAA therapy. Patients on low or moderate doses of corticosteroids for four or more weeks or any dose for less than one week. Patients receiving intra-articular corticosteroid therapies. Understanding HBVr

For individuals who have had hepatitis B, the virus can sometimes become active again later in life, a process known as hepatitis B reactivation. HBVr can cause significant liver damage, including acute liver failure in severe cases, the need for a liver transplant, and even death.

Certain groups with chronic hepatitis B or prior exposure to hepatitis B are at increased risk of HBVr, particularly those taking medications that suppress the immune system. These medications include:

Chemotherapy and biologic therapies for cancer treatment. Immunosuppressive medications for inflammatory conditions such as inflammatory bowel disease, rheumatologic diseases such as rheumatoid arthritis, and dermatologic conditions such as psoriasis. Transplant medications for solid organ or bone marrow recipients. Corticosteroids, especially when used for extended periods (more than a few weeks and/or high dose). Hepatitis C treatments with DAA. Patients with HIV infection. By understanding these risks, health care providers can take proactive steps to prevent HBVr in vulnerable patients.

###

AGA Media Contact: Annie Mehl, Communications and Media Relations Manager, media@gastro.org, 301-327-0013

About the AGA Institute

The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice, and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. www.gastro.org

AGA is on Instagram.
Like AGA on Facebook.
Follow us on X @AmerGastroAssn and Bluesky @amergastroassn.bsky.social.
  Check out our videos on YouTube.
Join AGA on LinkedIn.

About Gastroenterology
Gastroenterology is the most prominent journal in the field of gastrointestinal disease. As the official journal of the AGA Institute, Gastroenterology delivers up-to-date and authoritative coverage of both basic and clinical gastroenterology. Regular features include articles by leading authorities and reports on the latest treatments for diseases. Original research is organized by clinical and basic-translational content, as well as by alimentary tract, liver, pancreas, and biliary content. www.gastrojournal.org/

END

ELSE PRESS RELEASES FROM THIS DATE:

Adults diagnosed with ADHD may have reduced life expectancies

2025-01-23

Adults who have been diagnosed with attention deficit hyperactivity disorder (ADHD) may be living shorter lives than they should, finds a world-first study led by UCL researchers. The research, published in The British Journal of Psychiatry, analysed anonymised primary care data from 30,029 adults across the UK with diagnosed ADHD. They then compared this group with 300,390 participants without ADHD, who were matched by age, sex, and primary care practice. The researchers found an apparent reduction in life expectancy for men with diagnosed ADHD of between 4.5 and 9 years, and between 6.5 and 11 years for women. Senior author, ...

Rare pterosaur fossil reveals crocodilian bite 76m years ago

2025-01-23

The fossilised neck bone of a flying reptile unearthed in Canada shows tell-tale signs of being bitten by a crocodile-like creature 76 million years ago, according to a new study published today [23 January] in the Journal of Palaeontology. The juvenile pterosaur vertebra, discovered in Dinosaur Provincial Park, Alberta, bears a circular four-millimetre-wide puncture mark from a crocodilian tooth. Researchers from the Royal Tyrrell Museum of Palaeontology (Canada), the University of Reading (UK) and the University of New England (Australia) say this rare evidence provides insight into predator-prey dynamics ...

Thousands of European citizen scientists helped identify shifts in the floral traits of insect-pollinated plants

2025-01-23

The results of cowslip observations carried out with the help of citizen scientists from 32 countries in over 5,200 locations shed light on the well-being of insect-pollinated plants under changing climate and land use conditions. The study was made possible thanks to the contribution of European science enthusiasts. It revealed some surprising results recently published in the Journal of Ecology, one of the longest-standing top-level journals in this field. The cowslip (Primula veris) is considered a model species for studying insect-pollinated plants. Cowslips can have two types of flowers: long-styled (L-morph) and short-styled (S-morph). In L-morph flowers, ...

By the numbers: Diarylethene crystal orientation controlled for 1st time

2025-01-23

Photomechanical materials made of photochromic crystals, which change their molecular structure reversibly in response to light, have the potential to impact fields from semiconductors to pharmaceuticals. For the first time in the world, an Osaka Metropolitan University team has developed a crystal patterning method demonstrating that it is possible to control the orientation of photochromic crystals known as diarylethenes. Diarylethene crystals not only change color when exposed to UV light, but also undergo various shape changes as the molecular structure ...

HKU physicists pioneer entanglement microscopy algorithm to explore how matter entangles in quantum many-body systems

2025-01-23

Quantum entanglement – a phenomenon where particles are mysteriously linked no matter how far apart they are – presents a long-standing challenge in the physical world, particularly in understanding its behaviour within complex quantum systems. A research team from the Department of Physics at The University of Hong Kong (HKU) and their collaborators have recently developed a novel algorithm in quantum physics known as ‘entanglement microscopy’ that enables visualisation and mapping of this extraordinary phenomenon at a microscopic scale. By zooming in on the intricate ...

Solving the evolutionary puzzle of polyploidy: how genome duplication shapes adaptation

2025-01-23

Evolution is the basis of biological diversity, driven by mechanisms that allow organisms to adapt and survive. One such mechanism is polyploidy, where organisms carry extra copies of their genomes. While polyploidy provides genetic redundancy by allowing mutations without affecting survival, it can also slow evolutionary progress by diluting beneficial mutations. This paradox has intrigued scientists for many years now, and a recent study from Earth-Life Science Institute (ELSI) at Institute of Science Tokyo offers new insights into polyploidy's role in evolution. Led by ELSI’s ...

Smoking opioids is associated with lower mortality than injecting but is still high-risk

2025-01-23

A new study published today in the scientific journal Addiction has found that opioid smoking appears to be associated with lower mortality risk compared with opioid injecting. The authors, however, caution that opioid smoking still carries a substantial overdose risk and that these results should not be interpreted as suggesting that opioid smoking is safe. The study analysed substance use treatment data from 2006 to 2021, comparing 287,481 individuals who reported smoking opioids as their primary form of substance use and an equal weighted number of individuals who reported ...

WPIA: Accelerating DNN warm-up in web browsers by precompiling WebGL programs

2025-01-23

Deep learning techniques are drawing more and more attention to Web developers. A lot of Web apps perform inference of deep neural network (DNN) models within Web browsers to provide intelligent services for their users. Typically, GPU acceleration is required during DNN inference, especially on end devices. However, it has been revealed that GPU acceleration in Web browsers has an unacceptably long warm-up time, harming the quality of service (QoS). To solve the problems, a research team led by Yun MA published their new research on ...

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study

2025-01-23

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free ...

Camel milk udderly good alterative to traditional dairy

2025-01-23

Camel milk udderly good alterative to traditional dairy In addition to being hypoallergenic, camel milk could potentially protect the gut from harmful enzymes and create healthier digestion. New research from Edith Cowan University (ECU) has found that camel milk contained more naturally occurring bioactive peptides when compared to its bovine counterpart. “This is a good thing. We now know that camel milk has the potential to be hypoallergenic compared to cow’s milk, but also that it has higher potential to yield bioactive peptides which can have antimicrobial ...